Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452696 | 0.87 | — | — | |
| SCHEMBL1682010 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRCYP3A4L3MBTL1MAPK1 | |
| SCHEMBL8162693 | 0.84 | TSHR (0.44) | ALDH1A1TSHRCYP3A4L3MBTL1TDP1 | |
| SCHEMBL6544195 | 0.84 | HIF1A (0.37) | ALDH1A1TSHRHIF1A | |
| SCHEMBL9407160 | 0.82 | — | — | |
| SCHEMBL9407161 | 0.82 | — | — | |
| SCHEMBL2870652 | 0.82 | — | — | |
| SCHEMBL269289 | 0.81 | — | — | |
| SCHEMBL1579394 | 0.81 | — | — | |
| SCHEMBL23412066 | 0.81 | ALOX15 (0.36) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371133-A1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | APELLIS PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2008109180-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371133-A1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | C5, C3AR1, C1QBP | ALDH1A1 671/4885TSHR 2729/4885CYP3A4 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.